Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: A prospective observational multicentric study

Chiara Pecori, Marta Giannini, Emilio Portaccio, Angelo Ghezzi, Bahia Hakiki, Luisa Pastò, Lorenzo Razzolini, Andrea Sturchio, Laura De Giglio, Carlo Pozzilli, Damiano Paolicelli, Maria Trojano, Maria G. Marrosu, Francesco Patti, Gian L. Mancardi, Claudio Solaro, Rocco Totaro, Maria R. Tola, Giovanna De Luca, Alessandra LugaresiLucia Moiola, Vittorio Martinelli, Giancarlo Comi, Maria P. Amato

Research output: Contribution to journalArticle

Abstract

Background: Most of Multiple Sclerosis (MS) patients undergo disease modifying drug (DMD) therapy at childbearing age. The objective of this prospective, collaborative study, was to assess outcomes of pregnancies fathered by MS patients undergoing DMD.Methods: Structured interviews on pregnancies fathered by MS patients gathered in the Italian Pregnancy Dataset were collected; pregnancies were divided according to father exposure or unexposure to DMD at time of procreation. Treatment were compared with multivariable logistic and linear models.Results: Seventy-eight pregnancies fathered by MS patients were tracked. Forty-five patients were taking DMD at time of conception (39 beta-interferons, 6 glatiramer acetate), while 33 pregnancies were unexposed to DMD. Seventy-five pregnancies ended in live-births, 44 in the exposed and 31 in the unexposed group. No significant differences between the two groups were found in the risk of spontaneous abortion or malformations (p > 0.454), mean gestational age (p = 0.513), frequency of cesarean delivery (p = 0.644), birth weight (p = 0.821) and birth length (p = 0.649). In comparison with data of the Italian general population, the proportion of spontaneous abortion and caesarean delivery in exposed pregnancies fell within the estimates, while the proportion of pre-term delivery in the exposed group was higher than expected.Conclusions: Our data indicate no association between paternal DMD exposure at time of conception and risk of spontaneous abortion, adverse fetal outcomes and congenital malformations. Further studies clarifying the role of DMD fathers intake prior and during pregnancy are desirable, to supply guidelines for clinical practice.

Original languageEnglish
Article number114
JournalBMC Neurology
Volume14
Issue number1
DOIs
Publication statusPublished - May 20 2014

Keywords

  • Glatiramer acetate
  • Interferon beta
  • Multiple sclerosis
  • Paternity
  • Pregnancy

ASJC Scopus subject areas

  • Clinical Neurology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: A prospective observational multicentric study'. Together they form a unique fingerprint.

  • Cite this

    Pecori, C., Giannini, M., Portaccio, E., Ghezzi, A., Hakiki, B., Pastò, L., Razzolini, L., Sturchio, A., De Giglio, L., Pozzilli, C., Paolicelli, D., Trojano, M., Marrosu, M. G., Patti, F., Mancardi, G. L., Solaro, C., Totaro, R., Tola, M. R., De Luca, G., ... Amato, M. P. (2014). Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: A prospective observational multicentric study. BMC Neurology, 14(1), [114]. https://doi.org/10.1186/1471-2377-14-114